BrainsWay is an industry leader in the field of transcranial magnetic stimulation (TMS). BrainsWay’s flagship Deep TMS technology is a non-invasive, well-tolerated outpatient treatment, clinically proven to treat psychiatric and neurological conditions.
BrainsWay has received FDA-clearance for both major depression (MDD) and obsessive compulsive disorder (OCD- De Novo) and is developing more applications outside of the US. The company also has approval in Canada, Japan and other Asian countries. BrainsWay continues to push the TMS envelope with multiple clinical studies and further research into novel indications.
BrainsWay was founded in 2003 and began trading on the NASDAQ in 2019 under the symbol BWAY.
Questions for the Investor Relations Department can be submitted through the form below.
Fields marked with an * are required.
Data Provided by Refinitiv. Minimum 15 minutes delayed.